Universal-Beteiligungs- und Servicegesellschaft
CARM

Universal-Beteiligungs- und Servicegesellschaft’s Carisma Therapeutics CARM Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200,000
Closed -$62K – 2019
2025
Q1 		$62K Buy
+200,000
New +$88.6K ﹤0.01% 1964

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's CARM Position: Q2 2025 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of Carisma Therapeutics (CARM) in Q2 2025, closing a stake of 200,000 shares — an estimated $62K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in CARM in Q1 2025 and held it in 1 quarter. The position peaked at $62K in Q1 2025. 36 funds tracked by Wall St. Rank hold CARM as of Q2 2025.

  • Universal-Beteiligungs- und Servicegesellschaft reported no remaining Carisma Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Universal-Beteiligungs- und Servicegesellschaft sold 200,000 Carisma Therapeutics shares in Q2 2025, an estimated $62K.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Carisma Therapeutics in Q1 2025 and held it in 1 quarter.
  • Universal-Beteiligungs- und Servicegesellschaft's Carisma Therapeutics position peaked at $62K in Q1 2025.
  • 36 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2025.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q2 2025, filed 11 Aug 2025.